Michael J. Mauro, MD, discusses updates presented at the 2017 ASH Annual Meeting and the advances that are on the horizon for patients with chronic myeloid leukemia.
Sara A. Hurvitz, MD, discusses the development of biosimilars and their potential use in the breast cancer field.
A new drug application has been filed with the FDA for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.
Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.
Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.
Niraparib (Zejula) met the primary endpoint of overall response as a fourth-line or later treatment in patients with ovarian cancer, regardless of BRCA status, according to top-line results from the QUADRA study.
The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.
A novel risk stratification and treatment approach led to enhanced clinical outcomes overall, as well as the successful omission of radiotherapy for some patients with stage IV favorable histology Wilms tumor and pulmonary metastases.
Alexander Drilon, MD, discusses genomic drivers in non–small cell lung cancer as well as the current treatment options for patients who harbor those mutations.
Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.